4-(2-(2-Iminothiazol-5(2H)-ylidene)hydrazinyl)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one

Catalog No. :
ACGBVB283
CAS No. :
303226-00-8
Molecular Formula :
C14H14N6OS
Molecular Weight :
314.37

IUPAC Name:(E)-4-(2-(2-iminothiazol-5(2H)-ylidene)hydrazineyl)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one

4-(2-(2-Iminothiazol-5(2H)-ylidene)hydrazinyl)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$70.00Login to see priceInquiryInquiry
100mg98%$101.00Login to see priceInquiryInquiry
250mg98%$132.00Login to see priceInquiryInquiry
1g98%$338.00Login to see priceInquiryInquiry
5g98%$947.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(2-(2-Iminothiazol-5(2H)-ylidene)hydrazinyl)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
IUPAC Name(E)-4-(2-(2-iminothiazol-5(2H)-ylidene)hydrazineyl)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
MDL No.MFCD06654905
Molecular FormulaC14H14N6OS
Molecular Weight314.37
SMILESCC1=C(N/N=C2\C=NC(=N)S2)C(=O)N(C2=CC=CC=C2)N1C
InChI KeyNXTDNWQDJHBKBR-HBLJHXSTSA-N
Synonym5(2H)-Thiazolone, 2-imino-, 2-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)hydrazone
CAS No.303226-00-8

Synthetic Route by SureRoute

1. ACGBVB283 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGBVB283 route product structure diagram
    ACGBVB283303226-00-8
Inquiry

2. ACGBVB283 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGBVB283 route product structure diagram
    ACGBVB283303226-00-8
Inquiry

Comments (0)